Transpire Bio has announced the initiation of its clinical program for a generic inhaler for the treatment of asthma and COPD. The company did not specify which of its pipeline products has been advanced into Phase 1. According to Transpire Bio’s web site, the company’s pipeline includes both a DPI and an MDI for asthma/COPD in addition to a DPI and SMIs for COPD.
In September 2022, Transpire announced that it had signed a deal with Recipharm for development of inhalers identified as TRB-3 and TRB-4 for asthma/COPD. Shortly after announcing the Recipharm (now Bespak) partnership, the company also signed a development agreement with INTO for three more inhalers.
Transpire Bio CEO Xian-Ming Zeng commented, “The dosing of the first human subject in our asthma and COPD inhaled drug program is an important milestone for Transpire Bio and represents a significant step toward our goal of becoming a world-leading inhalation medicines company. We believe that our special expertise in developing medicines via inhalation uniquely situates Transpire Bio for continued success in its mission to bring new therapies to patients.”
Read the Transpire Bio press release.
